A pilot study for treatment of severe COVID-19 pneumonia by aerosolized formulation of convalescent human immune plasma exosomes (ChipEXO™)

This is a single-center prospective, open-label, single arm interventional study to test the safety and efficacy of recently described ChipEXO™ for severe COVID-19 pneumonia. The ChipEXO™ is a natural product derived from convalescent human immune plasma of patients recovered from moderate COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Gül, Fethi, Gonen, Zeynep Burcin, Jones, Olcay Y., Taşlı, Neslihan Pakize, Zararsız, Gökmen, Ünal, Ekrem, Özdarendeli, Aykut, Şahin, Fikrettin, Eken, Ahmet, Yılmaz, Semih, Karakukçu, Musa, Kırbaş, Oğuz Kaan, Gökdemir, Nur Seda, Bozkurt, Batuhan Turhan, Özkul, Yusuf, Oktay, Burçin Doruk, Uygut, Muhammet Ali, Cinel, Ismail, Çetin, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682905/
https://www.ncbi.nlm.nih.gov/pubmed/36439138
http://dx.doi.org/10.3389/fimmu.2022.963309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682905/
https://www.ncbi.nlm.nih.gov/pubmed/36439138
http://dx.doi.org/10.3389/fimmu.2022.963309

Ejemplares similares